KRAS and non-small cell lung carcinoma: It is currently being evaluated in combination with FAK inhibitor defactinib in advanced KRAS-mutated NSCLC patients after failure of prior platinum-based chemotherapy and ICI, in combination with cetuximab in KRAS-mutant mCRC, as well as in combination with defactinib in recurrent LGSOC [111,112,113,114].